Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.
Fibromyalgia syndrome and connective tissue disorders were found to be highly associated in terms of both prevalence and symptoms.
What does the American College of Rheumatology recommend regarding discontinuing DMARD therapy in patients with rheumatoid arthritis? Test your knowledge with this quiz.
A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2022.
The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.
Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.
The percentage of patients with fibromyalgia experiencing alexithymia was substantially higher when compared with healthy controls and was linked to pain and psychological distress.
Beginning January 1, 2023, all new content and insights from the editorial teams of Rheumatology Network, Practical Cardiology and Endocrinology Network will be hosted on HCPLive.Com.
How do you assess if a patient with rheumatoid arthritis is in remission, and how should treatment be tapered for patients in remission? Test your knowledge with this quiz
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2022.
"Fibromyalgia is best managed as a chronic condition, with non-pharmacological therapies as the primary treatment and medications as an adjunct to symptom relief.”
Enrollment in the FIT Teens program, which began in January 2018, was paused in March 2020 to revise operations manuals, conduct remote treatment sessions to evaluate accuracy and fidelity, obtain regulatory approvals, and train staff on the new procedures.
The incidence of gout, the most common type of inflammatory arthritis in men, has increased globally in recent decades.
“Respiratory tract infections constitute the most common infections in patients with rheumatic diseases, especially under immunosuppressive treatment,” investigators explained.
Although previous studies have indicated differential effects on cardiovascular risk between immunomodulators, results showed similar reductions across both treatment groups.
Mymee, a self-advocacy platform, utilizes technological innovation, such as self-tracking, data analytics, and expert health coaching, to improve access and offer hope to these patients by uncovering their unique triggers, managing disease flares, and improving quality of life.
"Discovering your unique triggers can feel frustrating but with the right tools and support, it is possible to find answers," Hinton-Green emphasized. "You don’t have to do it alone."
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2022.
Dall'Era notes that it is important for rheumatologists to understand that the current endpoints for SLE clinical trials, such as SRI-4 and BICLA, are complex and imperfect.
The findings emphasize the severity of the potential methotrexate access problem.
Results indicated that the incidence of osteoporosis increased up to 4 times in younger male patients with gout when compared with those without gout.
Fibromyalgia commonly presents as widespread pain, physical, and cognitive symptoms. Unfortunately, it often manifests differently among patients and can be difficult to diagnose and treat.
Identifying the current prevalence and effect of fatigue on patients with psoriatic arthritis may lead to new strategies designed to manage this commonly-reported symptom.
A systematic review and meta-analysis assessing more than a dozen double-blind, placebo-controlled trials evaluating cannabis-based products for pain relief suggest these studies were the recipient of a disproportionate level of media coverage that was not associated with the results of each study.
Holding methotrexate after the second COVID-19 vaccine dose is associated with similar immunogenicity and a lower risk of disease flare compared with withholding methotrexate after both vaccine doses.
Take a few minutes to catch up on the latest rheumatology news for the month of November 2022.
Although the ACR and EULAR have introduced guidelines for initial treatment of Takayasu Arteritis, Robert Maughan, PhD, explains that there is little to no data available to guide decisions.
Thanksgiving marks the start of darker days and colder temperatures and acts as a reminder to get those annual booster shots for influenza and COVID-19. Test your knowledge on booster shots for patients with rheumatoid arthritis.
DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.